OptimizeRx (OPRX) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
Q2 2026 revenue was $20.5 million, down 30% year-over-year, but both revenue and adjusted EBITDA of $4.9 million exceeded consensus expectations despite declines driven by a small number of large customers and transition away from lower margin managed services.
Net revenue declined 21% year-over-year for the six months ended June 30, 2026, primarily due to the loss of a major customer and discontinuation of low-margin managed service programs.
Margin expansion and disciplined operational execution drove profitability, with gross margins expected to normalize in the high 60% to low 70% range for the full year.
Investments in AI-enabled platform capabilities, new product launches, and expanded programmatic initiatives are strengthening customer engagement and competitive positioning.
Leadership transition announced: Andy D'Silva to become CFO in 2027, with Ed Stelmakh remaining as strategic advisor.
Financial highlights
Q2 2026 revenue was $20.5 million, down from $29.2 million in Q2 2025; net revenue for H1 2026 was $40.3 million, down from $51.1 million in the prior year period.
Net loss of $0.7 million ($0.04 per share) in Q2 2026 vs. net income of $1.5 million ($0.08 per share) in Q2 2025; non-GAAP net income was $3.1 million ($0.16 per share) vs. $3.7 million ($0.19 per share) last year.
Adjusted EBITDA was $4.9 million in Q2 2026, down from $5.8 million in Q2 2025.
Operating cash flow for H1 2026 was $8.1 million; cash and cash equivalents stood at $24.1 million as of June 30, 2026.
Expenses decreased by $5.4 million year-over-year to $20.6 million, including $1.7 million in severance; cost of revenues as a percentage of revenue improved to 24% from 37% year-over-year.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $95–$100 million; adjusted EBITDA guidance at $21–$25 million.
Revenue expected to be weighted toward the second half, with Q4 likely representing 35–40% of full-year revenues.
Management expects macroeconomic headwinds, including inflation, tariffs, and industry-specific challenges, to continue impacting customer spending and revenue visibility over the next twelve months.
Profitability and margin improvements are expected to be sustainable, not episodic.
Rule of 40 remains a long-term objective, with expectations to return to that threshold in 2027 as growth resumes.
Latest events from OptimizeRx
- AI-powered healthcare platform drives pharma engagement and revenue growth.OPRX
Corporate presentation - Directors elected, executive pay and equity plan increase approved, evergreen provision rejected.OPRX
AGM 2026 - AI-powered point-of-care platform drives pharma ROI and growth through EHR integration and DSPs.OPRX
46th Annual William Blair Growth Stock Conference - Proposal seeks a five-year evergreen equity plan amendment with strong governance and oversight.OPRX
Proxy filing - Q1 2026 revenue fell 10%, but profitability improved and guidance remains strong.OPRX
Q1 2026 - Board recommends approval of all proxy proposals, including equity plan changes and auditor ratification.OPRX
Proxy filing - Scalable platform drives pharma brand engagement and revenue growth in a large digital market.OPRX
Corporate presentation - Record 2025 growth, margin expansion, and $10M buyback set a strong but cautious 2026 outlook.OPRX
Q4 2025 - Q2 2024 revenue up 36% to $18.8M, gross margin 62.2%, and strong DAAP momentum.OPRX
Q2 2024